US › Healthcare

CervoMed Inc. (CRVO)

US · Healthcare · Biotechnology

$2.80+7.69%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$0
Revenue YoY
-100.0%
Net profit
$-8.0M
Profit YoY
-62.7%
EPS
$-0.86
EPS estimate
$-0.79

EPS came in at -0.86 against a street estimate of -0.79 — a miss of 8.5%.

Key statistics

Market cap
$23.9M
Forward P/E
0.0
P/B
2.25
Book value
$1.15
EPS (TTM)
$-3.28
52-week high
$11.25
52-week low
$2.13
50-day MA
$3.12
200-day MA
$5.21
Beta
-4.42

Analyst view

Analysts rate CervoMed Inc. a strong buy (6 buy, 1 hold, 0 sell out of 7) with an average price target of $19.20.

Shareholding

Insiders
29.54%
Institutions
19.26%

Largest institutional holders

FundStake
Morgan Stanley - Brokerage Accounts5.47%
Vanguard Capital Management, LLC2.34%
Millennium Management LLC1.54%
Geode Capital Management, LLC0.55%
Renaissance Technologies Corp0.47%
BlackRock Inc0.38%
Byrne Asset Management LLC0.38%
XTX Topco Ltd0.28%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for CervoMed Inc. — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.